John Gever is a Freelance Writer at various publications. He focuses on medicine and healthcare, with a particular emphasis on immunology, immunotherapy, rheumatology, oncology, and healthcare technology. His work has been featured in Knowledia, MedPage Today, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
John Gever's coverage primarily focuses on medical research related to autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. He heavily relies on data in his articles. Given the nature of his work, he would likely be interested in hearing from experts who can provide insights into new research findings or clinical data related to autoimmune diseases and their treatment.
As a journalist covering scientific and healthcare topics with a strong emphasis on citing data, John may prefer sources who are actively involved in medical research or have access to significant clinical data that can support the points being made. Additionally, given the technical nature of his reporting, pitches should be tailored towards providing detailed scientific insights rather than general healthcare trends.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Key Takeaways Anifrolumab (Saphnelo) is approved for patients with systemic lupus erythematosus (SLE) and its efficacy for symptom relief has been demonstrated for up to 4 years.
By: John Gever
Quick, ultrasound-based assessment could readily be used in routine practice
— Another case series shows most patients improved markedly after failing everything else
— Chronic dosing at levels high enough to cause adverse effects remains common, French data show
By: John Gever
Patterns differ among medication classes; potential mechanisms need more research
John Gever Analysis of hundreds of thousands of patient records showed differing risks for autoimmune disorders for new users of the more recent types of antidiabetic medications.
— Early data provide reassurance Key Takeaways Chimeric antigen receptor (CAR) T-cell therapies have recently shown substantial
— "Serologically active, clinically quiescent" patients don't always stay that way Key Takeaways
By: John Gever
SLE patients with suboptimal drug exposure face increased heart risk
People taking hydroxychloroquine (HCQ) for systemic lupus erythematosus (SLE) showed markedly increased risk for atherosclerotic cardiovascular
